FY2025 sbir concept clearance award or topic development of therapeutic or preventative technologies for treatment or prevention of pediatric cancers and/or rare cancers
Active Definitive Contract Awarded Last action
- Contract number
- 75N91025C00011
- Awardee
-
ASO Therapeutics, Inc. UEI K8R9YHMX6Q31
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $299,991
Award facts
- Opportunity
-
- National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Innovative Concept Award Program – Fiscal Year 2025 Pre-Solicitation · 75N91024R00013 · Posted Mar 28, 2024
- Contract value 100% obligated
- $299,991.00 Current and potential, with all options
- Completion date 54% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 55 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- San Anselmo, CA 94901, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$55,000 | |
| Original award | $354,991 |
About this award
The National Cancer Institute awarded a $299,991 definitive contract to ASO Therapeutics, Inc. for development of a TBXT inhibitor for chordoma therapy on September 15, 2025, under a total small business set-aside.
This is an FY2025 SBIR Concept Clearance Award focused on therapeutic or preventative technologies for treatment or prevention of pediatric cancers and rare cancers. The originating solicitation, posted March 28, 2024, with a due date of April 12, 2024, sought proposals from small business concerns to perform research and development activities under the NCI Small Business Innovation Research program. Proposals were required to identify an anticipated product, the clinical problem, and cancer type(s) to be addressed, along with initial proof-of-concept data and a business model and commercialization plan. Place of performance is San Anselmo, California. The contract carries firm fixed price terms and an ultimate completion date of September 14, 2027.
Quick answers
Who was awarded contract 75N91025C00011?
75N91025C00011 was awarded to ASO Therapeutics, Inc. by National Cancer Institute (National Institutes of Health) on September 15, 2025.
How much is contract 75N91025C00011 worth?
The government has obligated $299,991 on 75N91025C00011.
Was contract 75N91025C00011 competed?
The extent of competition for 75N91025C00011 was full and open competition after exclusion of sources. The government received 55 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award